Neuropeptide Y expression in phaeochromocytomas

Relative absence in tumours from patients with von Hippel-Lindau syndrome

Susannah Cleary*, Jacqueline K. Phillips, Thanh Truc Huynh, Karel Pacak, Abdel G. Elkahloun, Jennifer Barb, Robert A. Worrell, David S. Goldstein, Graeme Eisenhofer

*Corresponding author for this work

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Phaeochromocytomas are rare neuroendocrine tumours that produce catecholamines and numerous secretory proteins and peptides, including neuropeptide Y (NPY), a vasoactive peptide with influences on blood pressure. The production of catecholamines and NPY by phaeochromocytomas is highly variable. This study examined influences of hereditary factors and differences in catecholamine production on tumour expression of NPY, as assessed by quantitative PCR, enzyme immunoassay and immunohistochemistry. Phaeochromocytomas included hereditary adrenaline-producing tumours (adrenergic phenotype) in multiple endocrine neoplasia type 2 (MEN 2), predominantly noradrenaline-producing tumours (noradrenergic phenotype) in von Hippel-Lindau (VHL) syndrome, and other adrenergic and noradrenergic tumours where there was no clear hereditary syndrome. NPY levels in phaeochromocytomas from VHL patients were lower (P<0.0001) than in those from MEN 2 patients for both mRNA (84-fold difference) and the peptide (99-fold difference). These findings were supported by immunohistochemistry. NPY levels were also lower in VHL tumours than in those where there was no hereditary syndrome. Relative absence of expression of NPY in phaeochromocytomas from VHL patients when compared with other groups appears to be largely independent of differences in catecholamine production and is consistent with a unique phenotype in VHL syndrome.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalJournal of Endocrinology
Volume193
Issue number2
DOIs
Publication statusPublished - May 2007
Externally publishedYes

    Fingerprint

Cite this